Indonesian Deputy Minister of Health and Others Visit Curatis Osong Bio Plant Site

Next-Generation mRNA COVID-19 Vaccine 'QTP104'
Discussion on Clinical Trials and Regulatory Approval Matters

[Asia Economy Reporter Lee Gwan-joo] Curatis announced on the 23rd that the Deputy Minister of Health of Indonesia and key officials visited the company's vaccine production facility, Osong Bio Plant.

Earlier, regarding the next-generation messenger RNA (mRNA) COVID-19 vaccine 'QTP104' currently under development, Curatis visited Indonesia on the 20th of last month to discuss clinical trials and regulatory approval matters in Indonesia and exchanged opinions on future cooperation plans.

This visit was a follow-up meeting to Curatis's previous visit to Indonesia. Indonesian health authorities inspected the production facility for the development of the next-generation mRNA COVID-19 vaccine and exchanged opinions on specific cooperation directions.

Curatis's next-generation mRNA COVID-19 vaccine 'QTP104' received approval for a Phase 1 clinical trial plan from the Ministry of Food and Drug Safety in July last year. Compared to conventional mRNA vaccines, it can induce a strong immune response with a smaller dose, and it is noted for safety as it does not contain PEG components, resulting in almost no allergic reactions.

Choi Yoo-hwa, Executive Director of Curatis, who oversees business development and clinical trials in Indonesia, said, "Through this Deputy Minister-level visit from the Indonesian Ministry of Health, we reaffirmed the willingness of both countries to cooperate and support overcoming COVID-19. We will continue to work closely with both governments to demonstrate the excellence of the domestically produced next-generation mRNA COVID-19 vaccine and strive to expand exports."